BINV

Bioinvent International

Market Cap 732.3M

Bioinvent är ett bioteknikbolag med säte i Lund, Sverige. Bolaget har ett ursprung från sitt antikroppsbibliotek n-CoDeR, som legat till grund för ett antal partneravtal och de egna projekten.   Verksamheten är framför allt inriktad på att ta fram antikroppsbaserade läkemedel mot cancer och under de senaste åren mer specifikt på det snabbt växande fältet immunonkologi (I/O). tf vd för bolaget är Björn Frendeus och organisationen uppgår till 56 anställda.  Bolaget har tre kliniska program BI-1206, för närvarande i fas I/II mot non-Hodgkins lymfom och kronisk lymfatisk leukemi, TB-403, i samarbete med Oncurious, för närvarande i fas I/II mot medulloblastom och delägda THR-317 som utvecklas för behandling av diabetiskt makulaödem. BioInvent har en spännande preklinisk portfölj baserad på nya immunmodulerande antikroppar riktade mot regulatoriska T-celler (T-reg) och tumörassocierade myeloidceller (TAM). I december 2016 undertecknade bolaget ett strategiskt forskningssamarbete med Pfizer Inc kring TAM. BioInvent arbetar även tillsammans med ledande akademiska institutioner, däribland University of Southampton, Cancer Research UK och Penn Medicine. BioInvent genererar intäkter från globala samarbetsavtal, med bland annat Bayer Pharma, Daiichi Sankyo och Mitsubishi Tanabe Pharma, samt från den egna anläggningen för produktion av antikroppar för forskning fram till kliniska prövningar i sen fas.  Under 2017 hade bolaget en omsättning på drygt 45 miljoner kronor som utgörs av ersättningar från partners och kontraktstillvkerning.  

+ more

Redeye Research

Reports

Notes

Today
Day High
2.10
2.04
Day Low
2.03
Day Open
2.08
Prev Close
2.07
VWAP
2.1
Volume
198K
Turnover
0.409M
Top Broker
AVA
VWAP
2.0
Avg Volume
379K
Avg Turnover
0.771M
Top Brokers
AVA/NON
VWAP
2.0
Avg Volume
447K
Avg Turnover
0.880M
Top Brokers
AVA/NON
VWAP
1.9
Avg Volume
367K
Avg Turnover
0.711M
Top Brokers
AVA/NON
52 week summary
Price Range
1.8
Last
3.0
Beta
N/A
Market Cap
732.3M
Total Return
-8.7%
Trailing P/E
-6.4
Div Yield
0.0%
Shares Outstanding
350.4M
Stock Exchange
NASDAQ Stockholm
5 day chart Go to advanced chart

Identify and measure trend strength in stocks with our Momentum tool to identify potential entry and exit signals. The tool provides a set of the most simple but powerful indicators that identify whether a stock is under sell or buy pressure.

Relative Price Strength
Change 3 Months -3.4%
Change 12 Months -8.2%
Volume Trend
Average Volume 10 vs 60 Days -35.6%
Price VS
52 Week High -30.8%
50 Day Moving Average 5.8%
200 Day moving Average -3.0%

Add article markers

Compare Bioinvent International to

Prev Close 0 Change 0
High 0 Avg Daily Volume 0
Low 0 Avg Daily Turnover 0
  • Management
  • tf Björn Frendéus, CEO
  • Stefan Ericsson, CFO
  • Executive board
  • Leonard Kruimer, Chairman of the board
  • Bernd Seizinger
  • An van Es-Johansson
  • Vincent Ossipow
  • Dharminder Chahal
  • Kristoffer Bissessar
Last updated: 2018-04-25 Source: Redeye
Major Owners Equity Votes
Adrianus Van Herk 8.7%
8.7%
Omega Funds Management Llc 8.5%
8.5%
Compagnie Mérieux Alliance 7.9%
7.9%
Pfizer Health AB 7.2%
7.2%
Avanza Pension 5.3%
5.3%
Nordnet Pensionsförsäkring 3.6%
3.6%
Mattias Cramby 2.9%
2.9%
Rhenman & Partners Asset Management 2.9%
2.9%
Peter Thelin 2.7%
2.7%
Peter Hoglin 2.4%
2.4%
Last updated: 2018-04-25 Source: Redeye/Holdings
Timeframe Transactions Net Shares
Last 12 weeks
1 Purchases
15,000
0 Sales
0
Last 24 weeks
1 Purchases
15,000
0 Sales
0
Report Date Name Position Transaction Shares Chg Est Value (SEK)

Catalyst Potential is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Source: Millistream
  •  
  • Profitability
  • ROE
  • ROCE
  • ROIC
  • EBITDA margin
  • EBIT margin
  • Net margin
  • Per share data (SEK)
  • EPS
  • EPS adj
  • Dividend
  • Net debt
  • Total shares
  • Valuation
  • EV (SEKm)
  • P/E
  • P/E diluted
  • P/Sales
  • EV/Sales
  • EV/EBITDA
  • EV/EBIT
  • P/BV
  • Capital structure
  • Equity ratio
  • Debt/equity ratio
  • Net debt(SEKm)
  • Capital employed(SEKm)
  • Capital turnover rate
  • (SEKm)
  • Net sales
  • Total operating costs
  • EBITDA
  • Depreciation
  • Amortization
  • Impairment charges
  • EBIT
  • Share in profits
  • Net financial items
  • Exchange rate dif.
  • Pre-tax profit
  • Tax
  • Net earnings
  • (SEKm)
  • Assets
  • Current assets
  • Cash in banks
  • Receivables
  • Inventories
  • Other current assets
  • Current assets
  • Fixed assets
  • Tangible assets
  • Associated comp.
  • Investments
  • Goodwill
  • Cap. exp. for dev.
  • O intangible rights
  • O non-current assets
  • Total fixed assets
  • Deferred tax assets
  • Total (assets)
  • Liabilities
  • Current liabilities
  • Short-term debt
  • Accounts payable
  • O current liabilities
  • Current liabilities
  • Long-term debt
  • O long-term liabilities
  • Convertibles
  • Total Liabilities
  • Deferred tax liab
  • Provisions
  • Shareholders' equity
  • Minority interest (BS)
  • Minority & equity
  • Total liab & SE
  • (SEKm)
  • Net sales
  • Total operating costs
  • Depreciations total
  • EBIT
  • Taxes on EBIT
  • NOPLAT
  • Depreciation
  • Gross cash flow
  • Change in WC
  • Gross CAPEX
  • Free cash flow
  • 2015
  •  
  • -221.5%
  • -232.1%
  • -3,938.7%
  • -586.0%
  • -596.4%
  • -569.4%
  •  
  • -0.56
  • -0.56
  • 0.00
  •  
  • 162.9
  •  
  • 577.4
  • -6.8
  • -6.8
  • 38.8
  • 36.3
  • -6.2
  • -6.1
  • 21.0
  •  
  • 54.1%
  • 0.0%
  • -40
  • -11
  • 0.3
  • 2015
  •  
  •  
  • 40
  • 13
  • 0
  • 0
  • 53
  •  
  • 1
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 1
  • 0
  • 54
  •  
  •  
  • 0
  • 0
  • 25
  • 25
  • 0
  • 0
  • 0
  • 25
  • 0
  • 0
  • 29
  • 0
  • 29
  • 54
  • 2015
  • 16
  • -109
  • -2
  • -95
  • 4
  • -91
  • 2
  • -89
  • 16
  • -1
  • -78
  • 2015 Q1
  • 1
  • -22
  • -21
  • 0
  • 0
  • 0
  • -22
  • 0
  • 0
  • 0
  • -22
  • 0
  • -22
  • 2015 Q2
  • 4
  • -28
  • -25
  • 0
  • 0
  • 0
  • -25
  • 0
  • 0
  • 0
  • -25
  • 0
  • -25
  • 2015 Q3
  • 2
  • -24
  • -22
  • 0
  • 0
  • 0
  • -23
  • 0
  • 0
  • 0
  • -23
  • 0
  • -23
  • 2015 Q4
  • 10
  • -35
  • -25
  • 0
  • 0
  • 0
  • -25
  • 0
  • 0
  • 0
  • -25
  • 4
  • -21
  • 2016
  •  
  • -48.1%
  • -48.2%
  • 597.6%
  • -86.8%
  • -88.2%
  • -87.8%
  •  
  • -0.21
  • -0.21
  • 0.00
  •  
  • 304.7
  •  
  • 709.3
  • -15.0
  • -15.0
  • 13.1
  • 10.0
  • -11.5
  • -11.3
  • 4.1
  •  
  • 83.4%
  • 0.0%
  • -226
  • 4
  • 0.3
  • 2016
  •  
  •  
  • 226
  • 43
  • 2
  • 0
  • 271
  •  
  • 6
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 6
  • 0
  • 276
  •  
  •  
  • 0
  • 0
  • 46
  • 46
  • 0
  • 0
  • 0
  • 46
  • 0
  • 0
  • 230
  • 0
  • 230
  • 276
  • 2016
  • 71
  • -133
  • -1
  • -63
  • 0
  • -63
  • 1
  • -62
  • -11
  • -5
  • -78
  • 2016 Q1
  • 29
  • -29
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 2016 Q2
  • 10
  • -37
  • -27
  • 0
  • 0
  • 0
  • -27
  • 0
  • 0
  • 0
  • -27
  • 0
  • -27
  • 2016 Q3
  • 1
  • -29
  • -28
  • 0
  • 0
  • 0
  • -29
  • 0
  • 0
  • 0
  • -28
  • 0
  • -28
  • 2016 Q4
  • 31
  • -38
  • -7
  • 0
  • 0
  • 0
  • -7
  • 0
  • 0
  • 0
  • -7
  • 0
  • -7
  • 2017
  •  
  • -55.7%
  • -55.8%
  • -2,327.8%
  • -217.1%
  • -223.6%
  • -223.0%
  •  
  • -0.33
  • -0.33
  • 0.00
  •  
  • 304.7
  •  
  • 497.0
  • -6.3
  • -6.3
  • 14.0
  • 11.0
  • -5.1
  • -4.9
  • 4.8
  •  
  • 76.6%
  • 0.0%
  • -134
  • -4
  • 0.3
  • 2017
  •  
  •  
  • 134
  • 15
  • 2
  • 0
  • 151
  •  
  • 19
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • 19
  • 0
  • 170
  •  
  •  
  • 0
  • 0
  • 40
  • 40
  • 0
  • 0
  • 0
  • 40
  • 0
  • 0
  • 130
  • 0
  • 130
  • 170
  • 2017
  • 45
  • -143
  • -3
  • -101
  • 0
  • -101
  • 3
  • -98
  • 21
  • -16
  • -93
  • 2017 Q1
  • 13
  • -35
  • -22
  • 0
  • 0
  • 0
  • -22
  • 0
  • 0
  • 0
  • -22
  • 0
  • -22
  • 2017 Q2
  • 11
  • -35
  • -23
  • 0
  • 0
  • 0
  • -24
  • 0
  • 0
  • 0
  • -23
  • 0
  • -23
  • 2017 Q3
  • 7
  • -28
  • -21
  • 0
  • 0
  • 0
  • -21
  • 0
  • 0
  • 0
  • -21
  • 0
  • -21
  • 2017 Q4
  • 14
  • -44
  • -31
  • -2
  • 0
  • 0
  • -33
  • 0
  • 0
  • 0
  • -33
  • 0
  • -33
  • 2018 E
  • 2018 E
  • 2018 E
  • 2018 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2019 E
  • 2020 E
  • 2020 E
  • 2020 E
  • 2020 E

Estimated Values is behind membership

To access members-only content, you must login or register an account.

Our membership is about gaining access to unique research and knowledge through our analysts and a network of peers. Be the first to get information about news and research in the Nordic life science and technology sectors and use our tools and education to reach your personal and professional goals in investing.

Last updated: 2018-03-09 Source: Redeye
Source: Redeye

Presentations, research interviews and videos from our events listed here.

Source: Redeye

When selecting comparable companies, we try to group companies that are in the same or similar sector or subsector. But, more important, have growth, margins and risk characteristics similar to the company being valued.